Huatai Chenguang Pharmaceutical announced that it has received $8,918,200 in funding led by Jiangsu Haisheng Investment Management Co., Ltd. on September 10, 2020. The transaction included participation from CSC Financial Co., Ltd, Jiangsu Addor Equity Investment Fund Management Co., Ltd., and BGI Genomics Co., Ltd.